LumiSTAR Biotechnology, Inc.

LumiSTAR is developing a pipeline of innovative cell therapies based on induced pluripotent stem cell (iPSC) technology. These therapies have the potential to revolutionize the treatment of a wide range of diseases, including neurodegenerative diseases such as Parkinsons and Alzheimers, kidney failure and cancer. Other than cell therapy, the company also equipped with iPSC and bioimaging-based high throughput drug screening platform to develop new drugs. The platform uses iPSC to create disease models for drug discovery and screening, allowing for more accurate and efficient identification of potential drug candidates

High throughput drug screening,pre-clinical research,induced pluripotent stem cell (ipsc) technology,optogenetic tools,machine learning for phenotypic screening,organs-on-chips for personalized medicine,customized screening platform,genetically encoded tools,and ipsc cell therapy

Lumistar biotechnology, inc. operates in the Biotechnology industry.

Lumistar biotechnology, inc.'s revenue is 11m - 100m

Lumistar biotechnology, inc. has 11 - 50 employees.